Date:February 08, 2013

Malcolm Brenner, MD, PhD

Malcolm Brenner, M.D., Ph.D.Professor
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Dr. Malcolm Brenner
1102 Bates Street, Suite 1640.02
Houston, TX 77030

Phone: 832-824-4671
Fax: 832-825-4688


About Dr. Malcolm Brenner

Dr. Malcolm Brenner is a member of the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist, which is responsible for the stem cell transplant programs at these institutions. Dr. Malcolm Brenner’s clinical interests span many aspects of stem cell transplantation, using genetic manipulation of cultured cells to obtain therapeutic effects. Dr. Malcolm Brenner’s laboratory research focuses on manipulating the anti-leukemic effector function to kill residual cancer cells after stem cell transplantation. Efforts in Dr. Malcolm Brenner’s laboratory to analyze the cell of origin when relapse occurs in patients with acute myelogenous leukemia led Dr. Malcolm Brenner’s team to be the first to label autologous bone marrow cells genetically after purging, prior to their being reintroduced to the patient. Dr. Malcolm Brenner is studying the effects of gene transfer into autologous neuroblastoma cells and the use of gene-modified EBV-specific cytotoxic T lymphocyctes for prevention and treatment of lymphoproliferative disorders, Hodgkin’s disease, lung cancer and neuroblastoma.

Dr. Malcolm Brenner is a member of the Center for Cell and Gene Therapy (CAGT) research laboratories.


M.B.Ch.B., Cambridge University, London, England
Ph.D., Cambridge University, London, England
Fellowship, Royal College of Pathologists
Fellowship, Royal College of Physicians

Board Certifications

UK only

Selected Memberships

President, International Society for Hematology and Graft Engineering
Member, British Society for Hematology
Member, British Society for Immunology

Clinical Interests

Cell and Gene Therapy
Bone Marrow Transplantation


One interest of Dr. Malcolm Brenner’s research is in the field of tumor immunology. Tumor cells that have been genetically modified to express immunostimulatory genes will induce effective anti-tumor responses in a range of syngeneic animal models.

Dr. Malcolm Brenner has compared the relative immunostimulatory and anti tumor potency of autologous and allogeneic tumor vaccines in children with advanced neuroblastoma and in adult with acute and chronic leukemia. Recipients of both autologous and allogeneic vaccines showed evidence of local immunity but the autologous vaccine showed more potent systemic activity. In follow up studies, the immunogenicity of the tumor cells was increased by transducing them with a combination of lymphotactin, a T lymphocyte chemotaxin, and IL2, to amplify the response of tumor specific T cells attracted to the site of tumor inoculation. This approach has been extended to individuals with minimal residual disease. Similar studies are also underway in patients with acute and chronic leukemia. Dr. Malcolm Brenner’s laboratory is also using molecular techniques to increase the effectiveness of cytotoxic T cell killing of tumor cells.

Dr. Malcolm Brenner is Associate Editor of Blood and of Molecular Therapy and the Principal Investigator or Co-investigator on 5 NIH grants.

Dr. Malcolm Brenner is a member of the Center for Cell and Gene Therapy (CAGT) research laboratories.